Business
Aspire is an early-stage biopharmaceutical company developing sublingual delivery technology for known drugs, with high-dose sublingual aspirin discussed in the filing.
Aspire had only $6.2K of revenue, a $24.5M net loss, and negative equity in FY2025.
The read at a glance✓ Audited against SEC data
- Business mix — Sublingual drug deliveryNote
- Revenue — Revenue was $6.2KWatch
- Profitability — Net loss was $24.5MWatch
- Cash — FCF was -$4.9MWatch
- Balance sheet — Equity fell to -$6.4MWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Altman-Z distressWatch
Where the revenue comes from
Fiscal 2025, as Aspire Biopharma Holdings, Inc. reports it. History and quarterly detail are in the app.
- Nutraceutical Products$6K
Leadership changes
From Aspire Biopharma Holdings, Inc.'s own filings, the day they're filed.
- Donald G. Fell · directors · departureeff. 2026-02-06
- Surendra Ajjarapu · Director · departureeff. 2026-01-07
- Michael Howe · Chief Executive Officer · departureeff. 2025-07-24
Latest filings
- 8-K · Company announcement2026-08-19
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-06-22
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aspire Biopharma Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.